Brief: FDA Approves Atebrioz For Fibrodysplasia Ossificans Progressiva In Adults, Pediatric Patients
25/09/2026 22:48
BRIEF-FDA Approves Atebrioz For Fibrodysplasia Ossificans Progressiva In Adults, Pediatric Patients Sept 25 (Reuters) - FDA:
FDA: APPROVES ATEBRIOZ (ZILURGISERTIB) FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA IN ADULTS & PEDIATRIC PATIENTS 12 YEARS + - WEBSITE
FDA: ATEBRIOZ RECOMMENDED DOSAGE 100 MG ONCE DAILY
Further company coverage: INCY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incyte
See all newsIncyte Corp reports results for the quarter ended September 30 - Earnings Summary
Incyte Q3 adjusted loss per share beats estimates
Revolution Medicines falls after Incyte posts competitive pancreatic cancer data
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler